Exelixis Inc EXEL:NASDAQ

Last Price$20.94NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/28/22

Today's Change-1.28(5.76%)
Bid (Size)$20.62 (3)
Ask (Size)$21.26 (3)
Day Low / High$20.56 - 22.28
Volume3.0 M
  • Latest Stories
  • Commentary and Analysis
Exelixis Shares Rise After BMO Capital Starts Coverage at Outperform
2:11PM ET 6/24/2022 MT Newswires

Exelixis (EXEL) shares were up more than 3% in Friday afternoon trading after BMO Capital initiated the stock coverage at outperform and set the price...

BMO Capital Starts Exelixis at Outperform With $28 Price Target
4:54AM ET 6/24/2022 MT Newswires

Exelixis (EXEL) has an average rating of outperform and price targets ranging from $18 to $35, according to analysts polled by Capital IQ. (MT Newswires...

Exelixis Initiates Phase 3 Trial of Combination Treatment for Metastatic Colorectal Cancer; Shares Gain
10:49AM ET 6/21/2022 MT Newswires

Exelixis (EXEL) said Tuesday it has initiated a phase 3 trial evaluating its XL092 treatment in combination with either atezolizumab or regorafenib in...

Exelixis to Pay BioInvent $25 Million to Discover Cancer Antibodies
6:25AM ET 6/16/2022 MT Newswires

Exelixis (EXEL) said Wednesday that it entered an option and license agreement with Sweden's BioInvent International AB to discover new antibodies for...

Exelixis Details Results of Two Cancer Trials of Cabozantinib in Combination With Pembrolizumab, Atezolizumab
5:23PM ET 5/26/2022 MT Newswires

Exelixis (EXEL) said late Thursday a phase 2 trial of cabozantinib in combination with pembrolizumab in patients with recurrent or metastatic head and neck...

Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
4:32PM ET 5/10/2022 MT Newswires

Exelixis (EXEL) reported late Tuesday Q1 non-GAAP earnings of $0.26 per diluted share, compared with $0.09 a year earlier. Analysts polled by Capital IQ...

-- Earnings Flash (EXEL) EXELIXIS Posts Q1 EPS $0.26, vs. Street Est of $0.23
4:09PM ET 5/10/2022 MT Newswires


-- Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $356M, vs. Street Est of $363.2M
4:09PM ET 5/10/2022 MT Newswires


Earnings Reaction History: Exelixis Inc, 45.5% Follow-Through Indicator, 5.4% Sensitive
12:22PM ET 5/10/2022 MT Newswires

Expected Earnings Release: 05/10/2022, After-hours Avg. Extended-Hours Dollar Volume: $7,478,822 Exelixis Inc (EXEL) is due to issue its quarterly earnings...

Exelixis' Partner Ipsen Obtains European Commission Approval for Thyroid Cancer Treatment
12:29PM ET 5/03/2022 MT Newswires

Exelixis (EXEL) said Tuesday its partner Ipsen obtained European Commission approval for Cabometyx to treat adult patients with locally advanced or...